医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam

2022年11月23日 PM05:46
このエントリーをはてなブックマークに追加


 

AMSTERDAM

SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; hereafter “Shionogi”), officially opened the doors to its new European Headquarters in Herengracht, Amsterdam, today, marking the next stage of growth for the Japanese pharmaceutical company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005494/en/

Shionogi Amsterdam European Headquarters in Herengracht (Credit: Shionogi)

Shionogi Amsterdam European Headquarters in Herengracht (Credit: Shionogi)

The opening ceremony was conducted by His Excellency, Mr Hidehisa Horinouchi, Ambassador of Japan to the Netherlands, in the presence of Shionogi, Senior Executive Officer, Senior Vice President of Supply Supervisory Unit and Global Business Division, Dr. Koji Hanasaki. Others in attendance included guests from the Netherlands Foreign Investment Agency and Holland Bio, alongside the Shionogi Europe Executive Committee and all current employees based in the new office.

European CEO, Huw Tippett said: “The decision to open our new headquarters in Amsterdam was an easy one for the business. Amsterdam is a great city with a thriving life science community across both biopharmaceuticals and medical technology. It is renowned for its leading knowledge institutions, public-private partnerships, strategic location and of course the presence of key regulatory bodies such as the European Medicines Agency. The new office adds further strength to Shionogi’s European capabilities, as we continue on our ambitious growth journey”.

Shionogi has a long heritage in the development and marketing of anti-infectious disease treatments, as well as therapeutic areas such as haematology, women’s health, pain and central nervous system disorders. The office opening event coincides with World Anti-Microbial Resistance Awareness Week (WAAW) which Shionogi marked on Friday 18th November by participating in the World Health Organisation’s Go Blue campaign and lighting up the new Amsterdam office with blue lights.

Dr. Hanasaki said, “At Shionogi we are proud to have delivered treatments in areas of major public health concern and are steadfast in our pursuit to find even better solutions using our advanced scientific know-how, talented people and passion. A strong presence in Europe is vital to support our global vision of building innovation platforms to shape the future of healthcare, and I am delighted to be visiting the new office and forging new connections with the Netherlands business and science community”.

-ENDS-

For images or requests for interview contact Jo Taylor Executive Director, Corporate and Government Affairs on +44 (0)20 3053 4200

Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company has discovered and developed novel medicines for HIV, influenza and antimicrobial resistance and currently markets products in several therapeutic areas including anti-infectives. Other therapeutic areas, and the focus of the company’s pipeline, include CNS/psychoneurological diseases, oncology and pain.

Shionogi B.V. is a private limited liability company formed under Dutch law, trading as Shionogi Europe. Shionogi B.V. is registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180 and our registered address is Herengracht 464, 1017CA., please visit www.shionogi.eu.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005494/en/

CONTACT

Jo Taylor Executive Director, Corporate and Government Affairs

Shionogi Europe +44 (0)20 3053 4200

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Exscientia首次获得CTA核准,将启动EXS-21546治疗晚期实体瘤患者的1/2期IGNITE-AI试验
  • エクセンシア、進行性固形がん患者を対象としたEXS-21546の第1/2相試験IGNITE-AI開始のCTA承認を初めて取得
  • NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor’s TikTok Store in China and Expands Online Marketing in the U.S. and China
  • Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy
  • Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug